---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279818979.md"
description: "Novo Nordisk: Wegovy HD (Semaglutide 7.2 mg) has been approved in the United States. The drug has been shown to achieve a weight loss of 20.7%"
datetime: "2026-03-19T15:44:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279818979.md)
  - [en](https://longbridge.com/en/news/279818979.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279818979.md)
generator: "portal-rs"
---

# 

Novo Nordisk: Wegovy HD (Semaglutide 7.2 mg) has been approved in the United States. The drug has been shown to achieve a weight loss of 20.7%

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [600110.CN](https://longbridge.com/en/quote/600110.CN.md)

## Related News & Research

- [03:01 ETImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"](https://longbridge.com/en/news/296747920.md)
- [Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can](https://longbridge.com/en/news/296711443.md)
- [Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)](https://longbridge.com/en/news/296688992.md)
- [AMLX stock clocks best day ever after positive trial data, launches $350M offering](https://longbridge.com/en/news/296273366.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**